115 related articles for article (PubMed ID: 28595551)
1. NMR-based Drug Development and Improvement Against Malignant Melanoma - Implications for the MIA Protein Family.
Arnolds O; Zhong X; Tuo Yip K; Schöpel M; Kohl B; Pütz S; Abdel-Jalil R; Stoll R
Curr Med Chem; 2017; 24(17):1788-1796. PubMed ID: 28595551
[TBL] [Abstract][Full Text] [Related]
2. Extracellular SH3 domain containing proteins--features of a new protein family.
Stoll R; Bosserhoff A
Curr Protein Pept Sci; 2008 Jun; 9(3):221-6. PubMed ID: 18537677
[TBL] [Abstract][Full Text] [Related]
3. Backbone dynamics of the human MIA protein studied by (15)N NMR relaxation: implications for extended interactions of SH3 domains.
Stoll R; Renner C; Buettner R; Voelter W; Bosserhoff AK; Holak TA
Protein Sci; 2003 Mar; 12(3):510-9. PubMed ID: 12592021
[TBL] [Abstract][Full Text] [Related]
4. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold.
Stoll R; Renner C; Zweckstetter M; Brüggert M; Ambrosius D; Palme S; Engh RA; Golob M; Breibach I; Buettner R; Voelter W; Holak TA; Bosserhoff AK
EMBO J; 2001 Feb; 20(3):340-9. PubMed ID: 11157741
[TBL] [Abstract][Full Text] [Related]
5. Characterization and expression pattern of the novel MIA homolog TANGO.
Bosserhoff AK; Moser M; Buettner R
Gene Expr Patterns; 2004 Jul; 4(4):473-9. PubMed ID: 15183315
[TBL] [Abstract][Full Text] [Related]
6. Expression, function and clinical relevance of MIA (melanoma inhibitory activity).
Bosserhoff AK; Buettner R
Histol Histopathol; 2002 Jan; 17(1):289-300. PubMed ID: 11813878
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of p66shc by melanoma inhibitory activity.
Kasuno K; Naqvi A; Dericco J; Yamamori T; Santhanam L; Mattagajasingh I; Yang S; Meyskens FL; Bosserhoff AK; Irani K
Cell Death Differ; 2007 Aug; 14(8):1414-21. PubMed ID: 17431427
[TBL] [Abstract][Full Text] [Related]
8. Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins.
Lougheed JC; Holton JM; Alber T; Bazan JF; Handel TM
Proc Natl Acad Sci U S A; 2001 May; 98(10):5515-20. PubMed ID: 11331761
[TBL] [Abstract][Full Text] [Related]
9. Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition.
Schmidt J; Riechers A; Stoll R; Amann T; Fink F; Spruss T; Gronwald W; König B; Hellerbrand C; Bosserhoff AK
PLoS One; 2012; 7(5):e37941. PubMed ID: 22666418
[TBL] [Abstract][Full Text] [Related]
10. Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.
Yip KT; Zhong X; Seibel N; Arnolds O; Schöpel M; Stoll R
Biointerphases; 2017 May; 12(2):02D415. PubMed ID: 28565914
[TBL] [Abstract][Full Text] [Related]
11. The importance of melanoma inhibitory activity gene family in the tumor progression of oral cancer.
Sasahira T; Bosserhoff AK; Kirita T
Pathol Int; 2018 May; 68(5):278-286. PubMed ID: 29655307
[TBL] [Abstract][Full Text] [Related]
12. Detailed analysis of MIA protein by mutagenesis.
Stoll R; Lodermeyer S; Bosserhoff AK
Biol Chem; 2006 Dec; 387(12):1601-6. PubMed ID: 17132106
[TBL] [Abstract][Full Text] [Related]
13. Solution structure and dynamics of melanoma inhibitory activity protein.
Lougheed JC; Domaille PJ; Handel TM
J Biomol NMR; 2002 Mar; 22(3):211-23. PubMed ID: 11991352
[TBL] [Abstract][Full Text] [Related]
14. Mast cell chymase promotes angiogenesis and lymphangiogenesis mediated by activation of melanoma inhibitory activity gene family members in oral squamous cell carcinoma.
Kurihara-Shimomura M; Sasahira T; Shimomura H; Bosserhoff AK; Kirita T
Int J Oncol; 2020 May; 56(5):1093-1100. PubMed ID: 32319583
[TBL] [Abstract][Full Text] [Related]
15. Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma.
Yip KT; Zhong XY; Seibel N; Pütz S; Autzen J; Gasper R; Hofmann E; Scherkenbeck J; Stoll R
Sci Rep; 2016 May; 6():25119. PubMed ID: 27151361
[TBL] [Abstract][Full Text] [Related]
16. Melanoma inhibitory activity promotes melanoma development through activation of YBX1.
Schmid R; Meyer K; Spang R; Schittek B; Bosserhoff AK
Pigment Cell Melanoma Res; 2013 Sep; 26(5):685-96. PubMed ID: 23672612
[TBL] [Abstract][Full Text] [Related]
17. Processing of MIA protein during melanoma cell migration.
Schmidt J; Bosserhoff AK
Int J Cancer; 2009 Oct; 125(7):1587-94. PubMed ID: 19521988
[TBL] [Abstract][Full Text] [Related]
18. p54nrb is a new regulator of progression of malignant melanoma.
Schiffner S; Zimara N; Schmid R; Bosserhoff AK
Carcinogenesis; 2011 Aug; 32(8):1176-82. PubMed ID: 21642354
[TBL] [Abstract][Full Text] [Related]
19. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity.
Bosserhoff AK; Stoll R; Sleeman JP; Bataille F; Buettner R; Holak TA
Lab Invest; 2003 Nov; 83(11):1583-94. PubMed ID: 14615412
[TBL] [Abstract][Full Text] [Related]
20. Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression.
Bosserhoff AK
Pigment Cell Res; 2005 Dec; 18(6):411-6. PubMed ID: 16280006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
